Literature DB >> 29978384

Polymorphic analysis of CYP2C9 gene in Vietnamese population.

Nhung Phuong Vu1, Thuong Thi Huyen Ma1, Ngoc Thi Bich Tran1, Hue Thi Thu Huynh1, Ton Dang Nguyen1, Duong Thuy Nguyen1, Hai Van Nong1, Ming Ta Michael Lee2, Ha Hai Nguyen3.   

Abstract

Genetic variations in CYP2C9 are associated to inter-individual variability of drugs metabolism and response. The only report has been done previously mainly focusing on the common variant alleles of CYP2C9 in Vietnamese Kinh subjects. However, little is known about the complete spectrum of this gene polymorphism in different ethnic groups of Vietnam. We sequenced the promoter region and all exons of CYP2C9 in 100 healthy unrelated Vietnamese Kinh subjects. Additionally, common CYP2C9 variants, *2 and *3, were also analyzed by RFLP-PCR in extra 194 Kinh subjects and 279 of other four ethnic groups in Vietnam. The results of these common variants observed from five ethnic groups were compared with other populations in the world. Seven previously reported alleles and two genotypes were determined in Kinh subjects. The percentage of CYP2C9*1 and CYP2C9*3 alleles are 96.5 and 3.5%, respectively. We found one novel non-synonymous variant in exon 7 leading to amino acid change at 363 position from proline to histidine. Functional analysis by SIFT and Polyphen-2 indicated that this mutation is intolerant and probably damaging. Prevalence of CYP2C9*2 observed in Vietnamese population was significantly lower compared with that of other populations in the South and West of Asia as well as in Europe. This study provides information of genetic distribution pattern of CYP2C9 in Vietnamese, which would be useful for optimizing drug therapies in Vietnam.

Entities:  

Keywords:  CYP2C9 gene; Drug metabolism; Polymorphism; Sequencing; Vietnamese

Mesh:

Substances:

Year:  2018        PMID: 29978384     DOI: 10.1007/s11033-018-4235-3

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  21 in total

1.  Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.

Authors:  Maria Gabriella Scordo; Achille P Caputi; Concetta D'Arrigo; Giuseppina Fava; Edoardo Spina
Journal:  Pharmacol Res       Date:  2004-08       Impact factor: 7.658

2.  Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.

Authors:  Stuart A Scott; Rame Khasawneh; Inga Peter; Ruth Kornreich; Robert J Desnick
Journal:  Pharmacogenomics       Date:  2010-06       Impact factor: 2.533

3.  Genetic polymorphisms analysis of drug-metabolizing enzyme CYP2C9 in the Uyghur population.

Authors:  Tianbo Jin; Xiaojie Xun; Shuli Du; Tingting Geng; Hong Wang; Tian Feng; Chen Chen; Dongya Yuan; Longli Kang
Journal:  Xenobiotica       Date:  2015-11-26       Impact factor: 1.908

4.  Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.

Authors:  Negin Zand; Nader Tajik; Alireza Salek Moghaddam; Iraj Milanian
Journal:  Clin Exp Pharmacol Physiol       Date:  2007 Jan-Feb       Impact factor: 2.557

5.  CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia.

Authors:  H A Ngow; W M Wan Khairina; L K Teh; W L Lee; R Harun; R Ismail; M Z Salleh
Journal:  Singapore Med J       Date:  2009-05       Impact factor: 1.858

6.  CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database.

Authors:  D-P Dai; R-A Xu; L-M Hu; S-H Wang; P-W Geng; J-F Yang; L-P Yang; J-C Qian; Z-S Wang; G-H Zhu; X-H Zhang; R-S Ge; G-X Hu; J-P Cai
Journal:  Pharmacogenomics J       Date:  2013-02-12       Impact factor: 3.550

7.  Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C.

Authors:  M A Hamman; G A Thompson; S D Hall
Journal:  Biochem Pharmacol       Date:  1997-07-01       Impact factor: 5.858

8.  Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.

Authors:  A S Aynacioglu; J Brockmöller; S Bauer; C Sachse; P Güzelbey; Z Ongen; M Nacak; I Roots
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

9.  Predicting functional effect of human missense mutations using PolyPhen-2.

Authors:  Ivan Adzhubei; Daniel M Jordan; Shamil R Sunyaev
Journal:  Curr Protoc Hum Genet       Date:  2013-01

10.  Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.

Authors:  R A Stearns; P K Chakravarty; R Chen; S H Chiu
Journal:  Drug Metab Dispos       Date:  1995-02       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.